PARP inhibitors in the treatment of ovarian cancer: a review Recent findings:Niraparib received FDA approval for use in patients with complete response or partial response to first-line platinum-based chemotherapy ... CR Washington,KN Moore - 《Current Opinion in Obstetrics & Gynecology》 被引量...
AbbVie’s antibody-drug conjugate Elahere on Friday won the FDA’s full approval for the treatment of FRα-positive, platinum-resistant ovarian, fallopian tube and primary peritoneal cancers.
7,8]. The late diagnosis presents a major obstacle in the treatment of ovarian cancer leading to the steep decline in the survival rate from 89% within 5 years in stage I cancers to 41% in advanced stages [9]. In the
Are FDA-approved PARPi cost-effective as maintenance treatment of platinum-sensitive recurrent ovarian cancer?doi:10.1016/j.ygyno.2018.04.032Dottino J.A.Moss H.A.Lu K.H.Secord A.A.Havrilesky L.J.Gynecologic Oncology
treatment of platinum-resistant/refractory advanced ovarian cancer or HRD+ ovarian cancer in the late-line setting. Zejula received initial FDA approval in March 2017 for the maintenance treatment of adult patients wi...
The human genome contains regulatory elements, such as enhancers, that are often rewired by cancer cells for the activation of genes that promote tumorigenesis and resistance to therapy. This is especially true for cancers that have little or no known driver mutations within protein coding genes, ...
The Food and Drug Administration (FDA) has recently approved a selective neurotrophic tyrosine receptor kinase (NTRK) inhibitor, larotrectinib. Contemporarily, the development of multi-kinase inhibitors with activity in tumors carrying TRK fusions is ongoing. Chromosomal translocations involving the NTRK1...
While there are several ADCs under investigation to treat gynecologic cancers, mirvetuximab soravtansine is the only ADC that is currently FDA-approved for ovarian cancer. Mirvetuximab is an ADC composed of an FRα-binding antibody, a cleavable linker, and a maytansinoid DM4 (a tubulin-targe...
bevacizumab;ovarian cancer;anti-angiogenic;platinum–taxane;chemotherapy 1. Introduction For many years, the treatment of newly diagnosed ovarian cancer involved cytoreductive surgery and platinum/taxane chemotherapy [1]. In the past decade, incorporation of bevacizumab into front-line chemotherapy regimens ...
artificial intelligence; cancer research; imaging; clinical integration; radiomics1. Introduction Medical imaging is routinely used in clinical centres to detect and monitor various diseases. In particular, it is one of the pillars for the diagnosis and treatment monitoring of cancer, with computed ...